

# Michigan Prior Authorization Request Form For Prescription Drugs

## Instructions

**Important: Please read all instructions below before completing FIS 2288.**

Section 2212c of Public Act 218 of 1956, MCL 500.2212c, requires the use of a standard prior authorization form when a policy, certificate or contract requires prior authorization for prescription drug benefits.

A standard form, FIS 2288, is being made available to simplify exchanges of information between prescribers and health insurers as part of the process of requesting prescription drug prior authorization. This form will be updated periodically and the form number and most recent revision date are displayed in the top left hand corner.

- Prior authorization requests are defined as requests for pre-approval from an insurer for specified medications or quantities of medications before they are dispensed.
- Prescriber means the term as defined in section 17708 of the Public Health Code, 1978 PA 368, MCL 333.17708.
- Prescription drug means the term as defined in section 17708 of the Public Health Code, 1978 PA 368, MCL 333.17708.
- This form is made available for use by prescribers to initiate a prior authorization request.
- Insurers may request additional information or clarification needed to process a prior authorization request. The prior authorization is not considered granted if the prescriber fails to submit the additional information within 72 hours after the date and time of the original submission of a properly completed prior authorization request.
- In order to designate a prior authorization request for expedited review, a prescriber must certify that applying the 15-day standard review period may seriously jeopardize the life and health of the patient or the patient's ability to regain maximum function.

**Michigan Prior Authorization  
Request Form for Prescription Drugs** Fax: 858-790-7100

**Expedited Review Request:** *I hereby certify that a standard review period may seriously jeopardize the life or health of the patient or the patient's ability to regain maximum function.*  
Physician's Direct Contact Phone Number ( ) \_\_\_\_\_-\_\_\_\_\_ Initials: \_\_\_\_\_

**A) Reason for Request**

Initial Authorization Request       Renewal Request       DAW

**B) Patient Demographics**

Is patient hospitalized:    Yes    No

Patient Name: \_\_\_\_\_      DOB: \_\_\_\_\_

Patient Health Plan ID: \_\_\_\_\_

Male       Female

**C) Pharmacy Insurance Plan**

Priority    Magellan    Blue Cross Blue Shield of Michigan    HAP    \_\_\_\_\_

Total Health Care    Blue Care Network    HealthPlus of Michigan    Meridian Health Plan

**D) Prescriber Information**

Prescriber Name: \_\_\_\_\_      NPI: \_\_\_\_\_      Specialty: \_\_\_\_\_

DEA (required for controlled substance requests only): \_\_\_\_\_

Contact Name: \_\_\_\_\_      Contact Phone: \_\_\_\_\_      Contact Fax: \_\_\_\_\_

Health Plan Provider ID (if accessible): \_\_\_\_\_

**E) Pharmacy Information (optional)**

Pharmacy Name \_\_\_\_\_      Pharmacy Telephone \_\_\_\_\_

**F) Requested Prescription Drug Information**

Drug Name: \_\_\_\_\_      Strength: \_\_\_\_\_

Dosing Schedule: \_\_\_\_\_      Duration: \_\_\_\_\_

Diagnosis (specific) with ICD#: \_\_\_\_\_

Place of infusion / injection (if applicable): \_\_\_\_\_

Facility Provider ID / NPI: \_\_\_\_\_

Has the patient already started the medication?    Yes    No   If so, when? \_\_\_\_\_

**G) Rationale for Prior Authorization** (e.g., information such as history of present illness, past medical history, current medications, etc.; you may also attach chart notes to support your request if you believe they will assist with the review process)

**H) Failed/Contraindicated Therapies**

Drug Name	Strength	Dosing Schedule	Duration	Adverse Event/Specific Failure
_____	_____	_____	_____	_____
_____	_____	_____	_____	_____
_____	_____	_____	_____	_____

**I) Other Pertinent Information** (Optional - to be filled out if other information is necessary such as relevant diagnostic labs, measures of response to treatment, etc.) Please refer to plan's website for additional information that may be necessary for review. Please note that sending this form with insufficient clinical information may result in extended review period or adverse determination.

I represent to the best of my knowledge and belief that the information provided is true, complete and fully disclosed. A person may be committing insurance fraud if false or deceptive information with the intent to defraud is provided.

Physician's Name: \_\_\_\_\_

Physician's Signature: \_\_\_\_\_

Date: \_\_\_\_\_

PA 218 of 1956 as amended requires the use of a standard prior authorization form by prescribers when a patient's health plan requires prior authorization for prescription drug benefits.

**\*For Health Plan Use Only\***

Request Date: _____	LOB: _____
Approved: _____	Denied: _____
Approved By: _____	Denied By: _____
Effective Date: _____	Reason for Denial: _____
Additional Comments: _____	



**Michigan Department of Insurance and Financial Services**

DIFS is an equal opportunity employer/program.  
 Auxiliary aids, services and other reasonable accommodations are available upon request to individuals with disabilities.  
 Visit DIFS online at: [www.michigan.gov/difs](http://www.michigan.gov/difs) Phone DIFS toll-free at: 877-999-6442

**UNIVERSITY OF MICHIGAN – MULTAQ (dronedarone)**

Some of the information needed to make a determination for coverage is not specifically requested on the Michigan Prior Authorization Request Form for Prescription Drugs. To avoid delays in reviewing your request, please make sure to include all of the following information.

<b>To initiate therapy, respond to questions 1-5</b>		
1. Is the patient at least 18 years of age?	Y	N
2. Is the treatment indication for atrial arrhythmias, such as atrial fibrillation or atrial flutter?	Y	N
3. Does the patient have any of the following absolute contraindications? a. Any history of heart failure b. Second- or third- degree atrioventricular (AV) block or sick sinus syndrome without the presence of a functioning pacemaker c. QTc Bazett interval $\geq 500$ ms or PR interval $> 280$ ms d. Severe hepatic impairment e. Pregnancy	Y	N
4. Does the patient have any of the following relative contraindications? a. Concomitant use of a strong CYP3A inhibitor (i.e. ketoconazole, itraconazole, voriconazole, cyclosporine, telithromycin, clarithromycin, nefazodone, and ritonavir) b. Concomitant use of drugs or herbal products that prolong the QT interval and may induce Torsade de Pointes (i.e. phenothiazine anti-psychotics, tricyclic antidepressants, certain oral macrolide antibiotics, and Class I & II antiarrhythmics) c. Nursing mother	Y	N
5. During therapy, will the patient be monitored for the following? a. New or worsening heart failure b. Hypokalemia and hypomagnesemia with coadministration of potassium depleting diuretics c. QT interval prolongation d. Increase in creatinine after treatment initiation e. Abnormal liver function tests	Y	N
<b>Renewals, respond to questions 6-7</b>		
6. Within the past year, has an ECG been performed to monitor for response?	Y	N
7. Within the past year, has the patient experienced any of the following? a. New or worsening heart failure b. Hypokalemia and hypomagnesemia with coadministration of potassium depleting diuretics c. QT interval prolongation d. Increase in creatinine after treatment initiation e. Abnormal liver function tests	Y	N

Multaq is indicated for the cardiovascular hospitalization risk reduction in patients with a history of paroxysmal or persistent atrial fibrillation (AF) or atrial flutter (AFL), with a recent episode of AF/AFL, and associated cardiovascular risk factors, who are in sinus rhythm or who will be cardioverted.